Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Reports Full Year 2019 Results
Increased product and product-related services revenue over prior year, benefitting from expanded menu of profiling assays and increased number of customers adopting technology Released new HTG EdgeSeq Reveal data analysis software (version 2.0.0) Call scheduled for today, March 25 , at 4:30pm ET
Toggle Summary HTG Molecular Diagnostics to Announce Year End 2019 Financial Results and Host Conference Call on Wednesday, March 25
TUCSON, Ariz. , March 17, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2019 after the market close on Wednesday
Toggle Summary HTG Molecular to Present Corporate Overview at the SVB Leerink 9th Annual Global Healthcare Conference
TUCSON, Ariz. , Feb. 19, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the SVB Leerink 9 th Annual
Toggle Summary HTG EdgeSeq Mouse mRNA Tumor Response Panel Used by Researchers Targeting Cardiac Fibrosis with Engineered T-cells
TUCSON, Ariz. , Feb. 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG EdgeSeq Mouse mRNA Tumor Response Panel as a way to identify endogenous targets of cardiac
Toggle Summary HTG EdgeSeq miRNA Whole Transcriptome Assay is Highly Reproducible in Biofluids for Potential Use as a Biomarker
TUCSON, Ariz. , Feb. 05, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the reproducibility of the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA), as reported in a

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities